WO2013016566A1 - Procédés d'extraction de polyhydroxyalcanoates contenus dans des cellules bactériennes - Google Patents

Procédés d'extraction de polyhydroxyalcanoates contenus dans des cellules bactériennes Download PDF

Info

Publication number
WO2013016566A1
WO2013016566A1 PCT/US2012/048384 US2012048384W WO2013016566A1 WO 2013016566 A1 WO2013016566 A1 WO 2013016566A1 US 2012048384 W US2012048384 W US 2012048384W WO 2013016566 A1 WO2013016566 A1 WO 2013016566A1
Authority
WO
WIPO (PCT)
Prior art keywords
pha
bacterial cells
sodium
liquid
containing bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/048384
Other languages
English (en)
Inventor
Wade NIELSEN
Casey Mcgrath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Origin Materials Operating Inc
Original Assignee
Micromidas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromidas Inc filed Critical Micromidas Inc
Publication of WO2013016566A1 publication Critical patent/WO2013016566A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C12P7/625—Polyesters of hydroxy carboxylic acids

Definitions

  • the present disclosure generally relates to a process for producing polyhydroxyalkanoates (PHAs).
  • PHAs polyhydroxyalkanoates
  • the present disclosure relates to extracting PHAs from PHA-containing bacterial cells.
  • PHAs Polyhydroxyalkanoates
  • PHAs are linear polyester macromolecules composed of hydroxyl fatty acid monomer subunits.
  • PHBs polyhydroxybutyrate
  • PV polyhydroxy valerate
  • PHAs are typically UV-stable, resistant to a wide range of temperatures, and have attractive barrier properties.
  • PHA-based plastics may biodegrade when placed in environments that foster decomposition, such as landfills, composting sites, or aquatic environments.
  • PHA-based plastics may degrade quickly without any harmful effects on sea life or the greater ocean environment from chemical residues or other pollutants.
  • PHAs may also be biocompatible, gradually and harmlessly breaking down without inducing an inflammatory response in the body. As such, PHAs also have the potential to be useful for biomedical applications, such as medical sutures and tissue repair devices.
  • PHAs are produced by bacterial fermentation of sugar and lipids; however, extracting PHAs from these biological systems may require excising intracellular PHA granules.
  • Current extraction methods rely on a limited number of solvents that may dissolve PHA. These solvents are typically hazardous, highly regulated, toxic, expensive, or feature poor dissolution kinetics. Furthermore, drying steps may be needed, and processing difficulties may arise from the high viscosity of polymer solutions. As such, there exists a need in the art for a commercially viable process that can extract PHAs directly from PHA-containing bacterial cells.
  • the present disclosure addresses this need by providing a process for extracting PHAs from PHA-containing bacterial cells by lysing the cells and isolating the PHAs from the lysed cell debris.
  • One aspect of the present disclosure provides a process for isolating polyhydroxyalkanoate (PHA) from PHA-containing bacterial cells by: (a) providing PHA- containing bacterial cells suspended in a liquid; (b) contacting the PHA-containing bacterial cells suspended in the liquid with a base, a surfactant, or a combination thereof to form lysed cells; (c) adding a PHA anti-solvent to the lysed cells, wherein the PHA anti-solvent and the liquid releases PHA from the lysed cells; and (d) isolating the PHA from the lysed cells of step (c).
  • PHA polyhydroxyalkanoate
  • the liquid may include water, methanol, ethanol, propanol, butanol, acetone, acetonitrile, ethyl acetate, diethyl ether, chloroform, dichloromethane, dichloroethane, or any combination thereof.
  • the liquid may include water.
  • the base is ammonia, methyl amine, n-bromolithium, pyridine, acetylacetone, calcium hydroxide, bromine hydroxide, calcium oxide, magnesium hydroxide, sodium hydroxide, potassium hydroxide, alanine, or any combination thereof.
  • the base is sodium hydroxide.
  • the surfactant is ammonium lauryl sulfate, sodium laureth sulfate, sodium myreth sulfate, dioctyl sodium sulfosuccinate, perfluorooctanesulfonate, perfluorobutanesulfonate, Triton X 100, Triton X 114, 3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonate (CHAPS), deoxycholate (DOC), nonylphenol ethoxylate (NP-40), cetyltrimethylammonium bromide (CTAB), octyl thio glucosides, docusates, perfluorooctanoic acid (PFOA), perfluorooctanoate (PFO), sodium stearate, sodium dodecyl sulfate, or any combination thereof
  • the surfactant is sodium dodecyl sulfate.
  • the PHA-containing bacterial cells are contacted with a base and a surfactant.
  • the base and the surfactant are present in a weight ratio of about 0.1-10 to 1.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate.
  • the sodium hydroxide and the sodium dodecyl sulfate are present in a weight ratio of about 0.1-10 to 1.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate
  • the sodium hydroxide and the sodium dodecyl sulfate are present in a weight ratio of about 0.1-1 to 1 or 0.5-1 to 1.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate
  • the sodium hydroxide and the sodium dodecyl sulfate are present in a weight ratio of about 0.1 to 1, 0.2 to 1, 0.3 to 1, 0.4 to 1, 0.5 to 1, 0.6 to 1, 0.7 to 1, 0.8 to 1, 0.9 to 1, 1 to 1, 2 to 1, 5 to 1, or 10 to 1.
  • the base, the surfactant, and the liquid are present in a weight/ weight/ volume ratio of about 0.1-10 to 1 to 100.
  • the liquid includes water
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate
  • the sodium hydroxide, the sodium dodecyl sulfate and the water from the PHA-containing cell suspension are present in a weight/weight/volume ratio of about 0.1-10 to 1 to 100.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate
  • the sodium hydroxide, the sodium dodecyl sulfate and the water from the PHA-containing cell suspension are present in a weight/weight/volume ratio of about 0.1 to 1 to 100, 0.2 to 1 to 100, 0.3 to 1 to 100, 0.4 to 1 to 100, 0.5 to 1 to 100, 0.6 to 1 to 100, 0.7 to 1 to 100, 0.8 to 1 to 100, 0.9 to 1 to 100, 1 to 1 to 100, 2 to 1 to 100, 5 to 1 to 100, or 10 to 1 to 100.
  • the ratio of base to surfactant to water may also be expressed as a weight/weight/weight ratio.
  • the PHA-containing bacterial cells may be further lysed before adding the PHA anti-solvent.
  • the PHA-containing bacterial cells may be further lysed by employing a lysing solvent, a lysing enzyme, a bacteriophage, a beta-lactam antiobiotic, bleach, mechanical shear, pressure change, freeze and thaw, dessication, or any combination thereof.
  • Lysing solvents may include, for example, methanol, acetonitrile, acetone, acetic acid, ethanol, dioxane, tetrahydrofuran, hexane, heptane, ethyl acetate, toluene, chloroform, dichloromethane, dichloroethane, butyl acetate, xylene, or any combination thereof.
  • Lysing enzymes may include, for example, lysozyme, lysostaphin, zymolase, cellulose, mutanolysin, glycanases, proteases, mannose, or any combination thereof.
  • the PHA anti-solvent may include methanol, ethanol, propanol (e.g. , n-propanol, isopropanol), butanol (e.g.
  • the PHA anti-solvent is methanol.
  • the volume ratio of the PHA anti-solvent added to the liquid in the PHA-containing suspension is about 1-20 to 1. In other embodiments, the volume ratio of the PHA anti-solvent added to the liquid in the PHA-containing suspension is between about 1- 10 to 1. In certain embodiments, the volume ratio of PHA anti- solvent to the liquid is about 1 to 1, 1.5 to 1, 2.5 to 1, 3 to 1, 4 to 1, 5 to 1, 6 to 1, 10 to 1, 15 to 1, or 20 to 1.
  • the isolated PHA has a recovery of at least 30%. In other embodiments, the isolated PHA has a recovery of at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100%. In yet other embodiments, the isolated PHA has a recovery between 50-100%, 75-95%, or 80-90%.
  • the isolated PHA has a purity of at least 70%. In other embodiments, the isolated PHA has a purity of at least 75%, 80%, 85%, 90%, 95%, 99%, or 100%. In yet other embodiments, the isolated PHA has a purity of at least 70- 100%, 80- 100%, 90-100%, 70-95%, 80-95%, or 90-95%. In yet another embodiment, the isolated PHA has a purity of about 100%.
  • the PHA includes polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxyhexanoate (PHH), polyhydroxyoctanoate (PHO), polyhydroxydecanoate (PHD), polyhydroxybutyratevalerate (PHBV), or any combination thereof.
  • the PHA includes polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxybutyratevalerate (PHBV), or any combination thereof.
  • the PHA is PHB.
  • the PHA is a blend of PHB and PHV in a weight ratio of between 50:50 to 100:0.
  • the weight ratio of PHB to PHV in the PHA product is 50:50, 70:30, 80:20, 86: 14, 85: 15, or 90: 10.
  • the PHA is a blend of PHB and PHV, in which less than 35% by weight is PHV.
  • the PHA is a blend of PHB and PHV, in which less than 3%, between 15-25%, or between 30- 35% by weight is PHV.
  • step (a) includes: providing a carbonaceous feedstock; providing PHA-producing bacteria; and contacting the carbonaceous feedstock with PHA-producing bacteria to produce PHA-containing bacterial cells.
  • Another aspect of the present disclosure provides a process for isolating polyhydroxyalkanoate (PHA) from PHA-containing bacterial cells by: (a) providing PHA- containing bacterial cells suspended in a liquid; (b) contacting the PHA-containing bacterial cells suspended in the liquid with a base, a surfactant, or a combination thereof to form lysed cells; (c) adding methanol to the lysed cells, wherein the methanol and the liquid releases PHA from the lysed cells; and (d) isolating the PHA from the lysed cells of step (c).
  • PHA polyhydroxyalkanoate
  • the liquid may include water, methanol, ethanol, propanol, butanol, acetone, acetonitrile, ethyl acetate, diethyl ether, chloroform, dichloromethane, dichloroethane, or any combination thereof.
  • the liquid may include water.
  • the base is ammonia, methyl amine, n-bromolithium, pyridine, acetylacetone, calcium hydroxide, bromine hydroxide, calcium oxide, magnesium hydroxide, sodium hydroxide, potassium hydroxide, alanine, or any combination thereof.
  • the base is sodium hydroxide.
  • the surfactant is ammonium lauryl sulfate, sodium laureth sulfate, sodium myreth sulfate, dioctyl sodium sulfosuccinate, perfluorooctanesulfonate, perfluorobutanesulfonate, Triton X 100, Triton X 114, 3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonate (CHAPS), deoxycholate (DOC), nonylphenol ethoxylate (NP-40), cetyltrimethylammonium bromide (CTAB), octyl thio glucosides, docusates, perfluorooctanoic acid (PFOA), perfluorooctanoate (PFO), sodium stearate, sodium dodecyl sulfate, or any combination thereof
  • the surfactant is sodium dodecyl sulfate.
  • the PHA-containing bacterial cells are contacted with a base and a surfactant.
  • the base and the surfactant are present in a weight ratio of about 0.1- 10 to 1.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate.
  • the sodium hydroxide and the sodium dodecyl sulfate are present in a weight ratio of about 0.1- 10 to 1.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate
  • the sodium hydroxide and the sodium dodecyl sulfate are present in a weight ratio of about 0.1- 1 to 1 or 0.5- 1 to 1.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate
  • the sodium hydroxide and the sodium dodecyl sulfate are present in a weight ratio of about 0.1 to 1, 0.2 to 1, 0.3 to 1, 0.4 to 1 , 0.5 to 1, 0.6 to 1, 0.7 to 1, 0.8 to 1, 0.9 to 1, 1 to 1, 2 to 1, 5 to 1, or 10 to 1.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate
  • the sodium hydroxide, the sodium dodecyl sulfate and the water from the PHA-containing cell suspension are present in a weight/weight/volume ratio of about 0.1- 10 to 1 to 100.
  • the base is sodium hydroxide and the surfactant is sodium dodecyl sulfate
  • the sodium hydroxide, the sodium dodecyl sulfate and the water from the PHA-containing cell suspension are present in a weight/weight/volume ratio of about 0.1 to 1 to 100, 0.2 to 1 to 100, 0.3 to 1 to 100, 0.4 to 1 to 100, 0.5 to 1 to 100, 0.6 to 1 to 100, 0.7 to 1 to 100, 0.8 to 1 to 100, 0.9 to 1 to 100, 1 to 1 to 100, 2 to 1 to 100, 5 to 1 to 100, or 10 to 1 to 100.
  • the ratio of base to surfactant to water may also be expressed as a weight/weight/weight ratio.
  • the methanol and the water in the PHA-containing suspension may be present in a volume ratio of about 1-20 to 1. In other embodiments, the volume ratio of methanol added to the water in the PHA-containing suspension is between about 1- 10 to 1. In certain embodiments, the methanol and the water are present in a volume ratio of about 1 to 1, 1.5 to 1, 2.5 to 1, 3 to 1, 4 to 1, 5 to 1, 6 to 1, 10 to 1, 15 to 1, or 20 to 1.
  • the process further includes adding one or more additional extraction solvents that may include ethanol, propanol (e.g. , n-propanol, isopropanol), butanol (e.g.
  • the one or more additional extraction solvents is one, two, three, or four additional extraction solvents.
  • the PHA-containing bacterial cells may be further lysed before adding the methanol.
  • the PHA- containing bacterial cells may be further lysed by employing a lysing solvent, a lysing enzyme, a bacteriophage, a beta-lactam antiobiotic, bleach, mechanical shear, pressure change, freeze and thaw, dessication, or any combination thereof.
  • the isolated PHA has a recovery of at least 30%. In other embodiments, the isolated PHA has a recovery of at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100%. In yet other embodiments, the isolated PHA has a recovery between 50-100%, 75-95%, or 80-90%.
  • the isolated PHA has a purity of at least 70%. In other embodiments, the isolated PHA has a purity of at least 75%, 80%, 85%, 90%, 95%, 99%, or 100%. In yet other embodiments, the isolated PHA has a purity of at least 70-100%, 80-100%, 90-100%, 70-95%, 80-95%, or 90-95%. In yet another embodiment, the isolated PHA has a purity of about 100%.
  • the PHA includes polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxyhexanoate (PHH), polyhydroxyoctanoate (PHO), polyhydroxydecanoate (PHD), polyhydroxybutyratevalerate (PHBV), or any combination thereof.
  • the PHA includes polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxybutyratevalerate (PHBV), or any combination thereof.
  • the PHA is PHB.
  • the PHA is a blend of PHB and PHV in a weight ratio of between 50:50 to 100:0.
  • the weight ratio of PHB to PHV in the PHA product is 50:50, 70:30, 80:20, 86: 14, 85: 15, or 90: 10.
  • the PHA is a blend of PHB and PHV, in which less than 35% by weight is PHV.
  • the PHA is a blend of PHB and PHV, in which less than 3%, between 15-25%, or between 30- 35% by weight is PHV.
  • step (a) includes: providing a carbonaceous feedstock; providing PHA-producing bacteria; and contacting the carbonaceous feedstock with PHA-producing bacteria to produce PHA-containing cells.
  • Yet another aspect of the present disclosure provides a process for isolating polyhydroxyalkanoate (PHA) from PHA-containing bacterial cells by: (a) providing PHA- containing bacterial cells suspended in a liquid; (b) lysing the PHA-containing bacterial cells suspended in the liquid; (c) adding one or more extraction solvents to the lysed cells, wherein the one or more extraction solvents and the liquid releases PHA from the lysed cells; and (d) isolating the PHA from the lysed cells of step (c).
  • the liquid is water.
  • the liquid may include water, methanol, ethanol, propanol, butanol, acetone, acetonitrile, ethyl acetate, diethyl ether, chloroform, dichloromethane, dichloroethane, or any combination thereof.
  • the liquid may include water.
  • the lysing may employ a base, a surfactant, a lysing solvent, a lysing enzyme, a bacteriophage, a beta-lactam antiobiotic, bleach, mechanical shear, pressure change, freeze and thaw, dessication, or any combination thereof.
  • Suitable bases may include, for example, ammonia, methyl amine, n-bromolithium, pyridine, acetylacetone, calcium hydroxide, bromine hydroxide, calcium oxide, magnesium hydroxide, sodium hydroxide, potassium hydroxide, alanine, or any combination thereof.
  • the base is sodium hydroxide.
  • Suitable surfactants may include, for example, ammonium lauryl sulfate, sodium laureth sulfate, sodium myreth sulfate, dioctyl sodium sulfosuccinate, perfluorooctanesulfonate, perfluorobutanesulfonate, Triton X 100, Triton X 114, 3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonate (CHAPS), deoxycholate (DOC), nonylphenol ethoxylate (NP-40), cetyltrimethylammonium bromide (CTAB), octyl thio glucosides, docusates, perfluorooctanoic acid (PFOA), perfluorooctanoate (PFO), sodium stearate, sodium dodecyl sulfate, or any combination thereof.
  • PFOA perfluoroocta
  • the surfactant is sodium dodecyl sulfate.
  • Suitable lysing solvents may include, for example, methanol, acetonitrile, acetone, acetic acid, ethanol, dioxane, tetrahydrofuran, hexane, heptane, ethyl acetate, toluene, chloroform, dichloromethane, dichloroethane, butyl acetate, xylene, or any combination thereof.
  • Suitable lysing enzymes may include, for example, lysozyme, lysostaphin, zymolase, cellulose, mutanolysin, glycanases, proteases, mannose, or any combination thereof.
  • the one or more extraction solvents may include methanol, ethanol, propanol (e.g. , n-propanol, isopropanol), butanol (e.g.
  • the one or more extraction solvents is methanol.
  • the isolated PHA has a recovery of at least 30%. In other embodiments, the isolated PHA has a recovery of at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100%. In yet other embodiments, the isolated PHA has a recovery between 50-100%, 75-95%, or 80-90%.
  • the isolated PHA has a purity of at least 70%. In other embodiments, the isolated PHA has a purity of at least 75%, 80%, 85%, 90%, 95%, 99%, or 100%. In yet other embodiments, the isolated PHA has a purity of at least 70- 100%, 80- 100%, 90-100%, 70-95%, 80-95%, or 90-95%. In yet another embodiment, the isolated PHA has a purity of about 100%.
  • the PHA includes polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxyhexanoate (PHH), polyhydroxyoctanoate (PHO), polyhydroxydecanoate (PHD), polyhydroxybutyratevalerate (PHBV), or any combination thereof.
  • the PHA includes polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxybutyratevalerate (PHBV), or any combination thereof.
  • the PHA is PHB.
  • the PHA is a blend of PHB and PHV in a weight ratio of between 50:50 to 100:0.
  • the weight ratio of PHB to PHV in the PHA product is 50:50, 70:30, 80:20, 86: 14, 85: 15, or 90: 10.
  • the PHA is a blend of PHB and PHV, in which less than 35% by weight is PHV.
  • the PHA is a blend of PHB and PHV, in which less than 3%, between 15-25%, or between 30- 35% by weight is PHV.
  • step (a) includes: providing a carbonaceous feedstock; providing PHA-producing bacteria; and contacting the carbonaceous feedstock with PHA-producing bacteria to produce PHA-containing bacterial cells.
  • a method for isolating polyhydroxyalkanoate (PHA) from PHA-containing bacterial cells by: (a) providing PHA-containing bacterial cells suspended in a liquid comprising water; (b) contacting the PHA-containing bacterial cells suspended in the liquid with sodium hydroxide and sodium dodecyl sulfate to form lysed cells; (c) adding alcohol to the lysed cells, wherein the methanol and the liquid releases PHA from the lysed cells; and (d) isolating the PHA from the lysed cells of step (c).
  • PHA polyhydroxyalkanoate
  • the alcohol is Ci_6 alcohol. In one embodiment, the alcohol is methanol.
  • the sodium hydroxide and the sodium dodecyl sulfate are present in a weight ratio of about 0.1- 10 to 1.
  • the sodium hydroxide, the sodium dodecyl sulfate and the liquid are present in a weight/weight/volume ratio of about 0.1-10 to 1 to 100.
  • the volume ratio of the alcohol to the liquid is about 1-20 to 1.
  • the volume ratio of the methanol to the liquid is about 1-20 to 1.
  • the isolated PHA has a recovery of at least 30%. In other embodiments, the isolated PHA has a recovery of at least 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100%. In yet other embodiments, the isolated PHA has a recovery between 50-100%, 75-95%, or 80-90%.
  • the isolated PHA has a purity of at least 70%. In other embodiments, the isolated PHA has a purity of at least 75%, 80%, 85%, 90%, 95%, 99%, or 100%. In yet other embodiments, the isolated PHA has a purity of at least 70-100%, 80-100%, 90-100%, 70-95%, 80-95%, or 90- 95%. In yet another embodiment, the isolated PHA has a purity of about 100%.
  • the PHA includes polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxyhexanoate (PHH), polyhydroxyoctanoate (PHO), polyhydroxydecanoate (PHD), polyhydroxybutyratevalerate (PHBV), or any combination thereof.
  • the PHA includes polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxybutyratevalerate (PHBV), or any combination thereof.
  • the PHA is PHB.
  • the PHA is a blend of PHB and PHV in a weight ratio of between 50:50 to 100:0.
  • the weight ratio of PHB to PHV in the PHA product is 50:50, 70:30, 80:20, 86: 14, 85: 15, or 90: 10.
  • the PHA is a blend of PHB and PHV, in which less than 35% by weight is PHV.
  • the PHA is a blend of PHB and PHV, in which less than 3%, between 15-25%, or between 30- 35% by weight is PHV.
  • step (a) includes: providing a carbonaceous feedstock; providing PHA-producing bacteria; and contacting the carbonaceous feedstock with PHA-producing bacteria to produce PHA-containing bacterial cells.
  • FIG. 1 depicts an exemplary process for extracting polyhydroxyalkanoate (PHA) from PHA-containing bacterial cells by lysing the bacterial cells using sodium hydroxide and sodium dodecyl sulfate, and extracting the PHA using a methanol/water solvent system.
  • PHA polyhydroxyalkanoate
  • process 100 is an exemplary embodiment for extracting PHA from PHA-containing bacterial cells by using a methanol/water solvent system.
  • the PHA-containing bacterial cells in step 102 are Gram-negative bacteria that have produced intracellular PHA by fermenting sugars, fats, and fatty acids.
  • the PHA- containing bacterial cells are lysed by adding sodium hydroxide (i. e. , a base) and sodium dodecyl sulfate (i. e. , a surfactant).
  • step 106 methanol is added to the lysed cells to form a solvent system with the water from the PHA-containing cell suspension in step 102, in which the volume ratio of methanol to water is about 6 to 1.
  • the methanol used in the methanol/water extraction system helps purify the PHA by dissolving or partially dissolving some of the impurities (e.g. , lipids, proteins, DNA, RNA, and other cell debris).
  • solid PHA granules are suspended in the mixture with the lysed cells.
  • step 108 the solid PHA is isolated by filtration.
  • Process 100 includes optional step 110 to further purify the isolated PHA.
  • step 110 more methanol is added to re-suspend the isolated PHA, and the solid PHA is collected again by filtration. It should be understood that steps 106 and 108 may be repeated any number of times to purify the PHA.
  • process 100 may also include additional lysing steps (e.g. , bleaching, sonication, ross mixing, bead milling, microfluidization, and other shearing processes) before or after contacting the PHA-containing bacterial cells a base and/or a surfactant.
  • additional lysing steps e.g. , bleaching, sonication, ross mixing, bead milling, microfluidization, and other shearing processes
  • step 104 involving the use of base and surfactant may be omitted if there is already sufficient lysis.
  • process 100 may include a polishing step after isolating the solid PHA by filtration.
  • the polishing step may include, for example, dissolving the PHA into a solvent that has high PHA solubility, washing the PHA with other solvents that have low PHA solubility), and heating, reacting, or modifying the system in a way that will help remove impurities.
  • the term "about” refers to an approximation of a stated value within an acceptable range. Preferably, the range is +/- 10% of the stated value.
  • the PHA-containing bacterial cells used in exemplary process 100 are provided from bacterial fermentation of carbonaceous feedstock containing sugars, fats, and fatty acids.
  • the carbonaceous feedstock can be any material that contains carbon, and can serve as a source for producing PHAs.
  • Such materials may include one or more of animal manure, municipal sewage and wastewater, pulp waste, waste from food processing plants (e.g. , tomato paste production waste), agricultural waste, restaurant waste, yard waste, forest waste, other plant-based materials, biodiesel transesterification waste products (e.g. , glycerol), ethanol fermentation waste products (e.g. , thin stillage from corn or cane sugar), other fermentation or industrial process waste, or any combination of these materials.
  • biodiesel transesterification waste products e.g. , glycerol
  • ethanol fermentation waste products e.g. , thin stillage from corn or cane sugar
  • other fermentation or industrial process waste or any combination of these materials.
  • any methods known in the art may be used to provide the PHA-containing bacterial cells in process 100.
  • carbonaceous feedstock may be fermented to produce fatty acids (e.g. , butyrate, propionate, acetate, caproic acid, caprylic acid, capric acid, and lauric acid).
  • the fatty acids may be fermented by PHA-producing bacteria to produce PHA.
  • the bacteria are Gram-negative bacteria. Examples of bacteria suitable for PHA production may include Cupriavidus necator, Alcaligenes latus, Azotobacter, Comamonas, Pseudomonads, Burkholderia, and Delflia acidovorans.
  • Genetically-engineered organisms such as Cupriavidus, Escherichia coli, Klebsiella, and Delflia, may also be used to produce PHA.
  • bacteria suitable for PHA production may include Cupriavidus necator, Alcaligenes latus, Azotobacter, Comamonas, Pseudomonads, Burkholderia, and Delflia acidovorans.
  • Genetically-engineered organisms, such as Cupriavidus, Escherichia coli, Klebsiella, and Delflia may also be used to produce PHA.
  • PHA may be produced inside the bacteria, or released by the bacteria into the surrounding medium.
  • the process described herein, however, is directed to PHA-containing bacterial cells with intracellular PHA (i. e. , PHA produced inside the bacteria).
  • the PHA-containing bacterial cells in process 100 may be provided as a mixture of PHA-containing bacterial cells suspended in water or any other suitable liquid (e.g., methanol, ethanol, propanol, butanol, acetone, acetonitrile, ethyl acetate, diethyl ether, chloroform, dichloromethane, dichloroethane, or any combination thereof).
  • the PHA- containing bacterial cells are first isolated from the cell broth after fermentation to produce PHA before re-suspending the PHA-containing bacterial cells in water or any other suitable liquid.
  • the PHA-containing bacterial cells are already suspended in the cell broth after fermentation to produce PHA, and PHA is directly extracted from the cell broth suspension using the process described herein.
  • the PHA-containing bacterial cells are suspended in the cell broth after fermentation to produce PHA, and at least a portion of the cell broth liquid is removed before PHA is directly extracted from the cell broth suspension using the process described herein.
  • the volume of water or other suitable liquid used to suspend the PHA-containing bacterial cells may vary depending on cell-density of the suspension, and/or viscosity of the suspension.
  • the density of the PHA mixture is between 0.05-0.25 g/mL. In other embodiments, the density of the PHA mixture is between 0.05 to 0.2 g/mL. In certain embodiments, the density of the PHA mixture is about 0.1 g/mL. Lysine the PHA- Containing Bacteria Cells
  • sodium hydroxide and sodium dodecyl sulfate are used as the base and the surfactant, respectively, for lysing the PHA-containing bacterial cells.
  • “Lyse” or “lysing” refers to breaking or partially breaking down the walls of the PHA-containing bacterial cells, thereby making the PHA more available for isolation.
  • process 100 employs sodium hydroxide
  • suitable bases may include, for example, ammonia, methyl amine, n-bromolithium, pyridine, acetylacetone, calcium hydroxide, bromine hydroxide, calcium oxide, magnesium hydroxide, potassium hydroxide, and alanine. Any combination of the bases described above may also be used.
  • process 100 employs sodium dodecyl sulfate
  • other suitable surfactants may include, for example, ammonium lauryl sulfate, sodium laureth sulfate, sodium myreth sulfate, dioctyl sodium sulfosuccinate, perfluorooctanesulfonate, perfluorobutanesulfonate, Triton X 100, Triton X 114, CHAPS, DOC, NP-40, CTAB, octyl thio glucosides, docusates, perfluorooctanoic acid, perfluorooctanoate, and sodium stearate. Any combination of the surfactants described above may also be used.
  • the surfactant may be a cationic surfactant, an anionic surfactant, a non-ionic surfactant, or any combination thereof.
  • the base used may depend on the surfactant used. While process 100 employs sodium hydroxide and sodium dodecyl sulfate as the base/surfactant pair used for lysing cells, other base/surfactant combinations may be suitable.
  • the amount of base and surfactant used in process 100 may depend on the density of PHA mixture provided. The amount of base and surfactant used may affect the efficiency of lysis, and thus the PHA recovery yield.
  • the base is sodium hydroxide
  • the surfactant is sodium dodecyl sulfate
  • water is used in the PHA mixture
  • the ratio of sodium hydroxide (by weight) to sodium dodecyl sulfate (by weight) to water (by volume) is about 0.8 to 1 to 100.
  • the ratio of sodium hydroxide (by weight) to sodium dodecyl sulfate (by weight) to water (by volume) is about 0.1-10 to 1 to 100.
  • the ratio of sodium hydroxide (by weight) to sodium dodecyl sulfate (by weight) to water (by volume) is 0.1 to 1 to 100, 0.2 to 1 to 100, 0.3 to 1 to 100, 0.4 to 1 to 100, 0.5 to 1 to 100, 0.6 to 1 to 100, 0.7 to 1 to 100, 0.8 to 1 to 100, 0.9 to 1 to 100, 1 to 1 to 100, 2 to 1 to 100, 3 to 1 to 100, 4 to 1 to 100, 5 to 1 to 100, 6 to 1 to 100, 7 to 1 to 100, 8 to 1 to 100, 9 to 1 to 100, or 10 to 1 to 100. [0063] While FIG.
  • the PHA-containing bacterial cells may be lysed by any methods known in the art.
  • the PHA-containing bacterial cells may be lysed by contacting the bacteria with a base or an acid.
  • a lysis buffer may be used.
  • the surfactant may optionally be present.
  • a base and a surfactant are used.
  • Suitable methods to lyse the PHA-containing bacterial cells may include, for example, a lysing solvent, a lysing enzyme, a bacteriophage, a beta-lactam antiobiotic, bleach, mechanical shear, pressure change, freeze and thaw, dessication, sonication, or any combination of these methods.
  • Lysing solvents may include, for example, methanol, acetonitrile, acetone, acetic acid, ethanol, dioxane, tetrahydrofuran, hexane, heptanes, ethyl acetate, toluene, chloroform, dichloromethane, dichloroethane, butyl acetate, xylene, or any combination of these solvents.
  • Lysing enzymes may include, for example, lysozyme, lysostaphin, zymolase, cellulose, mutanolysin, glycanases, proteases, mannose, or any combination of these enzymes.
  • lysing the PHA-containing bacterial cells may further include heating the cell broth containing the PHA-containing bacterial cells to a temperature below the thermal degradation temperature of the PHA.
  • the temperature is between 50°C and 180°C.
  • the temperature is between 80°C and 120°C.
  • the temperature is about 100°C.
  • the pressure may need to be elevated. For example, to achieve a temperature above about 80°C when methanol and water are used as the extraction solvent system, the pressure may need to be increased. Furthermore, it should be understood that the pressure may affect the efficiency of lysis, and thus the PHA recovery yield.
  • the PHA extraction solvent system includes the liquid that suspends the PHA- containing bacterial cells and the one or more extraction solvents that are used to isolate the PHA.
  • the one or more extraction solvents form a mixture with the liquid suspending the PHA- containing bacterial cells. This mixture helps in releasing PHA from the lysed cell debris.
  • the mixture may solubilize or partially solubilize the lysed cell debris and other residual materials, such as residual acetic, butyric, propionic, and valeric acid, membrane lipids, other fatty acids, pyrrole compounds and the surfactant(s).
  • the mixture may also cause at least a portion of the PHA produced to dissociate from lysed cells.
  • the one or more extraction solvents may include solvents that have low PHA- solubility, but can solubilize the lysed cell debris and other residual materials.
  • the one or more extraction solvents may be a "PHA anti-solvent", which refers to any solvent in which PHA is poorly dissolved.
  • PHA is insoluble in the PHA anti-solvent, or less than 5%, less than 1%, or less than 0.1% of PHA by weight is soluble in the PHA anti-solvent.
  • the extraction solvents are PHA anti-solvents that form a suspension with the PHA.
  • the PHA is generally insoluble in the extraction solvent system, whereas the cellular debris and other residual materials are generally soluble in the extraction solvent system.
  • the one or more extraction solvents may be miscible with water.
  • Suitable extraction solvents may include, for example, methanol, ethanol, propanol (e.g. , n-propanol, isopropanol), butanol (e.g.
  • the liquid suspending the PHA-containing bacterial cells includes water and the extraction solvent is Ci_6 alcohol.
  • Ci_6 refers to the number carbons present.
  • Ci_6 alcohol has 1 to 6 carbons.
  • the extraction solvent is an alcohol selected from methanol, ethanol, propanol, butanol, isopropanol, and any combination of these solvents.
  • the extraction solvent is methanol.
  • the extraction solvent system used in the process described herein may depend on the constituents found in the carbonaceous feedstock.
  • the extraction solvent system may vary depending on the presence of high molecular weight fatty acids, insoluble salts, or other impurities that may be insoluble in the solvent system.
  • the number of extraction solvents used may vary. In some embodiments, one, two, three, or four solvents may be used. The ratio of the one or more extraction solvents to the liquid present in the PHA-containing suspension may affect the purity of the isolated PHA.
  • the methanol and the water are present in a volume ratio of about 1-20 to 1. In other embodiments, the methanol and water are present in a volume ratio of about 1- 10 to 1. In certain embodiments, the methanol and the water are present in a volume ratio of about 1 to 1, 1.5 to 1 , 2.5 to 1, 3 to 1 , 4 to 1, 5 to 1, 6 to 1, 10 to 1, 15 to 1, or 20 to 1.
  • a ratio of the one or more extraction solvents to the liquid present in the PHA-containing suspension that achieves optimal removal of the non-PHA components is used in the process described herein.
  • the optimal removal of non- PHA components may be achieved using a methanol concentration that solvates most of the lipids, but allows water to solvate the water-soluble components (e.g. , salts, fatty acids, sugars).
  • the PHA solids may be isolated from the solution containing the cellular debris and other residual materials by any solid/liquid separation methods known in the art (e.g. , gravity filtration, decanting, centrifugation, or screening).
  • the Isolated PHA The Isolated PHA
  • the isolated PHA extracted by the process described herein has a purity of at least 70%. In some embodiments, the isolated PHA has a purity of at least 80%, 85%, 90%, 95%, or 99%. In other embodiments, the isolated PHA has a purity between 80% and 95%. In yet other embodiments, the isolated PHA has a purity between 85% and 90%.
  • One skilled in the art would recognize the different techniques that may be used to determine purity, such as GPC, HPLC, GCMS, or GC-FID. It should be understood that the purity of the PHA may be increased by repeating the extraction process as depicted in optional step 114 (FIG. 1), and improving the effectiveness of lysing the PHA-containing bacterial cells.
  • the process described herein isolates PHAs with a recovery of at least 30%.
  • the PHAs are extracted from PHA-containing bacterial cells with a yield of at least 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 99.9%.
  • the recovery is between 30% and 99%.
  • the recovery is between 50% and 99%.
  • the recovery is between 90% and 99.9%.
  • the recovery is between 95% and 99%.
  • the term "recovery" or “extraction recovery” refers to the amount by weight of PHAs extracted from the PHA-containing bacterial cells relative to the amount by mass of PHAs produced in the cells before extraction.
  • the PHA extracted from the process described herein may be blend of polymers and/or co-polymers including, for example, polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), polyhydroxyhexanoate (PHH), polyhydroxyoctanoate (PHO), polyhydroxydecanoate, and polyhydroxybutyratevalerate (PHBV).
  • the blend of polymers and/or co-polymers may include straight-chained or branched PHAs that may be substituted with different functional groups. It should be understood that the fermentation bacteria, the operating conditions (e.g. , pH), and the feed constituents may affect the blend of polymers and/or co-polymers inside the PHA-producing bacteria.
  • the PHA product includes a blend of PHB and PHV.
  • the ratio of PHB and PHV may be between about 50:50 to 100:0. In some embodiments, the ratio of PHB to PHV in the PHA product may be about 50:50, 70:30, 80:20, 86: 14, 85: 15, 90: 10, or 100:0.
  • the PHA is a blend of PHB and PHV, in which less than 35% by weight is PHV. In yet certain embodiments, the PHA is a blend of PHB and PHV, in which less than 3%, between 15-25%, or between 30-35% by weight is PHV.
  • the isolated PHA may be further processed and converted into one or more plastics.
  • the biocompatible nature of PHA enables PHA-based plastics to be used in variety of biological applications, including medical sutures, tissue repair devices, or other biomedical uses.
  • This Example describes the production of a PHA mixture of PHA-containing bacterial cells suspended in water, in which the PHA was produced inside Gram-negative bacteria.
  • a 4L-reactor equipped with oxygen diffusion membranes, airlocks, and simethicone drip was used to grow Delftia Acidovorans bacteria to produce PHA.
  • the reactor system was prepared by boiling the feedstock, followed by cooling it to room temperature. The feedstock was then added to a previously sterilized 4L-reactor containing a solution of 7.50g sodium acetate, 8.78g sodium propionate, 3g nutrient broth, and 0.75g potassium phosphate in 3L of distilled water. The bacteria were incubated overnight at 25°C, pH 7, 30% dissolved oxygen.
  • the cell broth was then centrifuged for 10 minutes at 8,000g in a Sorvall RC 5B Plus Centrifuge and 25 °C. The supernatant was decanted, and a cell pellet containing PHA remained. The cell pellet was diluted in a 200mL beaker with lOOmL of distilled water to form a mixture of PHA-containing bacterial cells suspended in water.
  • This Example demonstrates the extraction of PHA from the mixture of PHA- containing bacterial cells suspended in water obtained from Example 1.
  • the PHA-containing bacterial cells are lysed, and then the PHA is extracted from the lysed debris using a methanol/water solvent system.
  • the extracted PHA was observed to be at least 100% pure with ⁇ 14% error.
  • the extraction was observed to work well for multiple types of PHAs, including PHB and PHV.
  • the PHA recovery was also determined by first analyzing the amount of PHA initially in the reactor.
  • the GC preparation hydrolysis solution can lyse and hydrolyze the entrained PHA granules, and offers a reading on the amount of PHA in a reactor system prior to processing.
  • the initial PHA content of the reactor was determined from the two samples taken prior to extraction, and is summarized in Table 2 below. Table 2. Reactor content of PHA
  • PHA loss may have occurred due to incomplete cell lysis, decomposition of PHA due to lysis conditions (e.g. , extreme pH and sonication), loss of PHA due to some minimal solubility in the methanol-water solution, or incomplete remove of PHA from the methanol-water solution due to Brownian suspension effects.
  • the amount of PHA lost in these steps may be reduced by optimizing the lysis procedure and by centrifuging at a higher speed to force separation of the PHA from the methanol solution.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé d'extraction de polyhydroxyalcanoates (PHA) contenus dans des cellules bactériennes. Le procédé permet d'extraire des PHA solides à partir de bactéries au moyen d'une base et d'un tensioactif pour lyser les cellules, et de deux ou de plus de deux solvants pour purifier les PHA libérés par les cellules lysées.
PCT/US2012/048384 2011-07-26 2012-07-26 Procédés d'extraction de polyhydroxyalcanoates contenus dans des cellules bactériennes Ceased WO2013016566A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161511962P 2011-07-26 2011-07-26
US61/511,962 2011-07-26

Publications (1)

Publication Number Publication Date
WO2013016566A1 true WO2013016566A1 (fr) 2013-01-31

Family

ID=46651605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048384 Ceased WO2013016566A1 (fr) 2011-07-26 2012-07-26 Procédés d'extraction de polyhydroxyalcanoates contenus dans des cellules bactériennes

Country Status (1)

Country Link
WO (1) WO2013016566A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210054048A1 (en) * 2018-02-26 2021-02-25 Purdue Research Foundation Rapid and simple purification of elastin-like polypeptides directly from whole cells and cell lysates by organic solvent extraction
CN115322342A (zh) * 2022-08-12 2022-11-11 哈尔滨工业大学 序贯式同步回收活性污泥中聚羟基脂肪酸酯和海藻酸盐的方法
CN115807044A (zh) * 2022-11-09 2023-03-17 华南理工大学 一种高效提取并纯化高纯度聚羟基脂肪酸酯的方法
WO2023210998A1 (fr) * 2022-04-26 2023-11-02 주식회사 윤바이오테크 Procédé de production de polyhydroxyalcanoate
CN118307814A (zh) * 2024-05-15 2024-07-09 淮北矿业绿色化工新材料研究院有限公司 一种聚羟基脂肪酸颗粒的制备方法
WO2024149069A1 (fr) * 2023-01-09 2024-07-18 北京微构工场生物技术有限公司 Procédé d'extraction de polyhydroxyalcanoate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1609868A1 (fr) * 2003-01-20 2005-12-28 Kaneka Corporation Procede permettant la collecte de polyhydroxyalcanoate tres pur a partir de cellules microbiennes
EP1705250A1 (fr) * 2003-12-19 2006-09-27 Tianan Biologic Material Co., Ltd. Ningbo Procede de separation, d'extraction et de purification de poly-beta-hydroxyalcanoates (pha) directement a partir d'un milieu de culture bacterien fermente

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1609868A1 (fr) * 2003-01-20 2005-12-28 Kaneka Corporation Procede permettant la collecte de polyhydroxyalcanoate tres pur a partir de cellules microbiennes
EP1705250A1 (fr) * 2003-12-19 2006-09-27 Tianan Biologic Material Co., Ltd. Ningbo Procede de separation, d'extraction et de purification de poly-beta-hydroxyalcanoates (pha) directement a partir d'un milieu de culture bacterien fermente

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACQUEL ET AL: "Isolation and purification of bacterial poly(3-hydroxyalkanoates)", BIOCHEMICAL ENGINEERING JOURNAL, ELSEVIER, AMSTERDAM, NL, vol. 39, no. 1, 8 December 2007 (2007-12-08), pages 15 - 27, XP022497886, ISSN: 1369-703X, DOI: 10.1016/J.BEJ.2007.11.029 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210054048A1 (en) * 2018-02-26 2021-02-25 Purdue Research Foundation Rapid and simple purification of elastin-like polypeptides directly from whole cells and cell lysates by organic solvent extraction
WO2023210998A1 (fr) * 2022-04-26 2023-11-02 주식회사 윤바이오테크 Procédé de production de polyhydroxyalcanoate
CN115322342A (zh) * 2022-08-12 2022-11-11 哈尔滨工业大学 序贯式同步回收活性污泥中聚羟基脂肪酸酯和海藻酸盐的方法
CN115807044A (zh) * 2022-11-09 2023-03-17 华南理工大学 一种高效提取并纯化高纯度聚羟基脂肪酸酯的方法
CN115807044B (zh) * 2022-11-09 2023-10-13 华南理工大学 一种高效提取并纯化高纯度聚羟基脂肪酸酯的方法
WO2024149069A1 (fr) * 2023-01-09 2024-07-18 北京微构工场生物技术有限公司 Procédé d'extraction de polyhydroxyalcanoate
CN118307814A (zh) * 2024-05-15 2024-07-09 淮北矿业绿色化工新材料研究院有限公司 一种聚羟基脂肪酸颗粒的制备方法

Similar Documents

Publication Publication Date Title
Koller Established and advanced approaches for recovery of microbial polyhydroxyalkanoate (PHA) biopolyesters from surrounding microbial biomass
Ong et al. An integrative study on biologically recovered polyhydroxyalkanoates (PHAs) and simultaneous assessment of gut microbiome in yellow mealworm
Madkour et al. PHA recovery from biomass
Kunasundari et al. Isolation and recovery of microbial polyhydroxyalkanoates.
JP5600333B2 (ja) ポリマー抽出法
WO2013016566A1 (fr) Procédés d'extraction de polyhydroxyalcanoates contenus dans des cellules bactériennes
Anis et al. Effect of different recovery strategies of P (3HB-co-3HHx) copolymer from Cupriavidus necator recombinant harboring the PHA synthase of Chromobacterium sp. USM2
BR112021011366A2 (pt) Produção de polihidroxialcanoatos a partir de correntes de resíduos de polpa e papel
Anis et al. Enhanced recovery and purification of P (3HB-co-3HHx) from recombinant Cupriavidus necator using alkaline digestion method
CA3110841C (fr) Composition de polymeres biodegradables et son procede de production
EP0669970A1 (fr) Degradation d'acides nucleiques par des peroxydes
CN1685048A (zh) 3－羟基链烷酸共聚物的精制方法
CN114250255A (zh) 一种高价值聚羟基脂肪酸酯的制备方法
JPH0731487A (ja) バイオポリエステル含有菌体からのバイオポリエステルの分離方法
CN116144046B (zh) 一种聚羟基脂肪酸酯凝集体的制备方法
Salmiati et al. Recovery of polyhydroxyalkanoates (PHAs) from mixed microbial cultures by simple digestion and saponification
CA2499607A1 (fr) Methode de coagulation de l'acide poly-3-hydroxyalcanoique
JP4007580B2 (ja) ポリヒドロキシアルカノエートの製造方法及び装置
KR20250055782A (ko) 메탄자화균으로부터 폴리하이드록시알카노에이트를 추출 및 회수하는 방법
WO2013016558A1 (fr) Procédés d'extraction et de purification de polyhydroxyalcanoates contenus dans des cellules bactériennes
Zain et al. Isolation and characterization of polyhydroxyalkanoates (PHAS) producing bacteria from brackish stream
CN114591499B (zh) 一种聚(r)-3-羟基丁酸酯的制备方法和应用
Espejo Alfonso Evaluation of different methods of extracting polyhydroxyoctanoate (PHO) produced from pseudomonas putida KT2440
CN118652944A (zh) 低分子量聚羟基脂肪酸酯及其制备方法与应用
Borges et al. Extraction of poly (3-hydroxybutirate) from Priestia megaterium using non-halogenated solvents: A comparative performance analysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12746429

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12746429

Country of ref document: EP

Kind code of ref document: A1